Intra-articular hyaluronic acid (viscosupplementation) for knee osteoarthritis
Dagenais S
Record ID 32006001110
English
Authors' objectives:
The aim of this bulletin is to provide an overview of intra-articular hyaluronic acid (viscosupplementation) for knee osteoarthritis.
Authors' recommendations:
In viscosupplementation, a glycosaminoglycan (GAG) called hyaluronic acid (HA) is administered via intra-articular (IA) injection for patients with knee osteoarthritis (OA).
Evidence suggests modest short-term reductions in pain and improvements in function, and no superiority among HA products.
Adverse events are rare, benign, temporary, and likely associated with the IA injection.
Economic analyses of mixed quality suggest that HA may be cost effective compared with usual care.
Clinical practice guidelines and evidence suggest that this approach is most suitable for patients with mild to moderate knee OA, and in those for whom other approaches are contraindicated, or have failed.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/E0010_viscosupplementation_cetap_e.pdf
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Injections, Intra-Articular
- Glycosaminoglycans
- Hyaluronic Acid
- Osteoarthritis, Knee
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.